| Actemra IV (tocilizumab) / Roche, JW Pharma |
| Not yet recruiting | 2 | 18 | | | Azienda Ospedaliero Universitaria di Parma, Roche | retroperitoneal fibrosis | | | | |
| Recruiting | 2 | 18 | | | Royal Brisbane and Women's Hospital, National Health & Medical Research Council | Acute graft versus host disease (GVHD) post HLA-matched allogeneic haematopoietic progenitor cell transplantation (HPCT) | | | | |
2015-001323-23: A study of Tocilizumab in patients with JIA associated Uveitis who have not responded to treatment with an anti-TNF. |
|
|
| Ongoing | 2 | 22 | Europe | Tocilizumab, Ro 487-7533/F10, Solution for injection in pre-filled syringe, Tocilizumab | University Hospitals Bristol NHS Foundation Trust, Roche | Juvenile Idiopathic Arthritis with Associated Uveitis, Arthritis with Uveitis, Diseases [C] - Eye Diseases [C11] | | | | |
2015-002799-26: A therapeutic trial of blockade of interleukin-6 using the drug Tocilizumab in pulmonary arterial hypertension |
|
|
| Ongoing | 2 | 26 | Europe | Concentrate for solution for infusion, RoActemra | Papworth Hospital NHS Foundation Trust | Pulmonary arterial hypertension, High blood pressure in the lungs, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2008-003011-12: Prospective Randomised Double-Blind Placebo Controlled Study Assessing the Efficacy of Tocilizumab with Synovial Analysis in Patients with Rheumatoid Arthritis |
|
|
| Ongoing | 2 | 30 | Europe | Tocilizumab, RO4877533, RoActemra®EV Product Code: PRD82321, RoActemra®EV Product Code: PRD82321 | University of Leeds | Rheumatoid Arthritis | | | | |
2016-003828-23: A pilot open-label study to assess the efficacy and safety of tocilizumab (TCZ) in patients with active Schnitzler’s syndrome (SchS) |
|
|
| Ongoing | 2 | 12 | Europe | RoActemra, Ro 487-7533/F10, Solution for injection, RoActemra | Charité - Universitätsmedizin Berlin; Dpt. of Dermatology and Allergy, ROCHE/CHUGAI Pharma AG | Schnitzler’s syndrome (SchS), Schnitzler’s syndromes characterized by chronic urticarial skin lesions associated with fever attacks, bone and muscle pain, arthralgia or arthritis, fatigue and lymphadenopathy., Diseases [C] - Immune System Diseases [C20] | | | | |
2016-004505-13: Tocilizumab for the Treatment of Familial Mediterranean Fever Tocilizumab zur Behandlung des Familiären Mittelmeerfiebers – Eine randomisierte, doppelblinde Phase II Studie - TOFFIFE |
|
|
| Ongoing | 2 | 30 | Europe | RoActemra® 20mg/ml Konzentrat Tocilizumab | University Hospital Tuebingen, Roche, University Hospital Tuebingen | Adult patients with Familial Mediterranean Fever, who have active disease, Familial Mediterranean Fever, Diseases [C] - Immune System Diseases [C20] | | | | |
| Ongoing | 2 | 66 | Europe | Solution for injection in pre-filled syringe, RoActemra | Linköping University, Region Östergötland | Major depressive disorder, Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-002595-41: Exploring the efficacy of tocilizumab as treatment for immunotherapy related side effects in cancer patients |
|
|
| Ongoing | 2 | 20 | Europe | Tocilizumab, Concentrate for solution for infusion, RoACTEMRA | Herlev and Gentofte Hospital, Bristol-Myers Squibb | Immune therapy related adverse events (arthritis and colitis) in patients with solid tumors, Side effects (diarrhea and arthritis) due to immunotherapy given to patients with cancer, Diseases [C] - Cancer [C04] | | | | |
2018-003142-16: Study to test treatment with two types of cells for influencing the immune system in kidney transplant patients |
|
|
| Not yet recruiting | 2 | 24 | Europe | Expanded Tregs_04, RegTivex-04, Injection, Infusion, RoActemra | Medical University of Vienna, Funding decision pending | Kidney transplantation., Kidney transplantation., Diseases [C] - Immune System Diseases [C20] | | | | |
2017-000519-18: PIMOC : Personalized targeted therapies in inflammatory complex multi organ disease Personnalisation des traitements de Pathologies Inflammatoires Multi Organes Complexes : PIMOC |
|
|
| Not yet recruiting | 2 | 32 | Europe | SECUKINUMAB, ADALIMUMAB, ANAKINRA, RITUXIMAB, TOCILIZUMAB, USTEKINUMAB, Solution for injection, Solution for infusion | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP), DGOS | Patients presenting inflammatory non classified disease targeting at least 2 organs involvement: skin, lymph nodes, hemopoietic system, joints, digestive tract. The disease has been resistant to at least two prior lines of treatment. Patient(e) présentant une maladie inflammatoire mal classée, impliquant au moins deux organes dont au moins la peau, et un des suivants : ganglions lymphatiques, système hématopoïétique, articulations, appareil digestif. La maladie a été résistante à au moins deux lignes de traitement., Patients presenting inflammatory non classified disease, resistant to prior treatment patients présentant une maladie inflammatoire non classée, sévère et résistante, Diseases [C] - Immune System Diseases [C20] | | | | |
2018-002790-22: Efficacy evaluation of tocilizumab in the treatment Graves' Orbitopathy Valutazione dell’efficacia di tocilizumab nel trattamento dell’orbitopatia basedowiana |
|
|
| Not yet recruiting | 2 | 64 | Europe | Roactemra, SOLU MEDROL, Tocilizumab, SOLU MEDROL, Concentrate for solution for infusion, Powder and solvent for solution for injection, ROACTEMRA - 20 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 4ML 1 FLACONCINO, SOLU MEDROL - 500 MG/8 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE DI POLVERE DA 500 MG+ FIALA SOLVENTE DA 8 ML | FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO, Roche S.p.A. | Active moderate-severe Graves' Orbitopathy Orbitopatia basedowiana di grado moderato-severo in fase attiva, Garcves' Orbitopathy in the zacute inflammatory phase Oftalmopatia di Basedow in fase infiiammatoria acuta, Diseases [C] - Hormonal diseases [C19] | | | | |
2018-004826-27: A phase 2 trial for patients with locally advanced or metastatic bile duct cancer investigating treatment with cisplatin and gemcitabine with or without tocilizumab. Et fase 2-forsøg for patienter med lokalt fremskreden eller spredt kræft i galdevejene, som behandles med cisplatin og gemcitabin med eller uden tocilizumab. |
|
|
| Not yet recruiting | 2 | 166 | Europe | Cisplatin, Gemcitabine, Concentrate for solution for infusion, RoActemra | Department of Oncology, Herlev & Gentofte Hospital, Department of Oncology, Herlev & Gentofte Hospital, Læge Sophus Carl Emil Friis og hustru Olga Doris Friis’ Legat | First-line treatment in patients with locally advanced or metastatic biliary tract cancer, inoperable due to extension of the disease., Locally advanced or metastatic biliary tract cancer Patienter med lokalt fremskreden eller spredt kræft i galdeveje, Diseases [C] - Cancer [C04] | | | | |
2020-001375-32: Early intervention with Tocilizumab in patients with COVID-19 and hypoxia Vroege interventie met Tocilizumab in patiënten met COVID-19 en zuurstoftekort |
|
|
| Ongoing | 2 | 354 | Europe | roactemra, Injection, Roactemra | UMCG, UMCG | Hypoxia, low oxygen, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2020-001770-30: Experimental use of tocilizumab in COVID-19 related pneumonia. |
|
|
| Ongoing | 2 | 60 | Europe | tocilizumab, Concentrate for solution for infusion, ROACTEMRA | CHU AMBROISE PARE, F. Hoffmann la roche | viral pneumonia caused by the new coronavirus (SARS-CoV-2), viral pneumonia caused by the new coronavirus (SARS-CoV-2), Diseases [C] - Virus Diseases [C02] | | | | |
2020-001408-41: Evaluation of efficacy and safety of an tocilizumab treatment in patients with severe COVID-19 pneumonia |
|
|
| Ongoing | 2 | 200 | Europe | Roactemra®, Solution for infusion, RoActemra® | Universitätsklinikum Freiburg, Universitätsklinikum Freiburg | Severe COVID-19 pneumonia, In many patients SARS-CoV2 causes a disease named COVID-19. In this trial patients with a pneumonia and severe respiratory insufficiency will be analyzed., Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2020-001995-13: Clinical trial to evaluate the efficacy and safety of tocilizumab for treating patients with COVID-19 pneumonia: the BREATH-19 Study Ensayo clínico para evaluar la eficacia y seguridad de tocilizumab en el tratamiento de pacientes con neumonía por COVID-19: estudio BREATH-19 |
|
|
| Ongoing | 2 | 500 | Europe | Concentrate for solution for infusion, Roactemra | Fundación SEIMC-GESIDA, Roche Farma | COVID-19 pneumonia Neumonía por COVID-19, COVID-19 pneumonia Neumonía por COVID-19, Diseases [C] - Virus Diseases [C02] | | | | |
ChiCTR2000030196: A multicenter, single arm, open label trial for the efficacy and safety of CMAB806 in the treatment of cytokine release syndrome of novel coronavirus pneumonia (COVID-19) |
|
|
| Not yet recruiting | 2 | 60 | China | conventional therapy+tocilizumab | Central South Hospital of Wuhan University; JinYu Bio-Technology Co., LTD., funds raised by oneself | cytokine release syndrome of new coronavirus pneumonia (COVID-19) | | | | |
| Withdrawn | 2 | 284 | NA | Analogs, Prostaglandin E1, Standard therapeutic protocol | Alonso Vera Torres | Covid19 | 12/20 | 12/20 | | |
2020-001087-28: Anti-IL6 receptor antibodies to reduce allo-sensitization post allograft nephrectomy Réduire le risque d'allo-immunisation après l'ablation du greffon rénal par utilisation d'un anticorps anti-IL6 récepteur |
|
|
| Not yet recruiting | 2 | 18 | Europe | RoActemra, Solution for injection in administration system, RoActemra | CHU Toulouse, CHU Toulouse | kidney transplantation Patient nécessitant une ablation du greffon après greffe rénale, greffe rénale graft nephrectomy, Body processes [G] - Immune system processes [G12] | | | | |
| Not yet recruiting | 2 | 50 | NA | Infliximab, Tocilizumab | Assistance Publique - Hôpitaux de Paris, DGOS | Takayasu Arteritis | 02/21 | 09/23 | | |
NCT04412291: A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study |
|
|
| Recruiting | 2 | 120 | Europe | Anakinra Prefilled Syringe, Tocilizumab Prefilled Syringe, Standard-of-care treatment, Oxygen supplementation, Thrombosis prophylaxis, Steroids, Antibiotics | Karolinska University Hospital, Karolinska Institutet | Covid-19 | 03/21 | 06/21 | | |
2018-000254-21: PIONEER is a clinical study in patients with squamous cell carcinoma of the head and neck that is amenable to surgical resection with curative intent. This study will determine the feasibility of preoperative immunotherapy with atezolizumab (Tecentriq®) with or without tocilizumab (Actemra®) |
|
|
| Not yet recruiting | 2 | 40 | Europe | Atezolizumab, tocilizumab, Concentrate for solution for infusion, Tecentriq, Actemra | University Hospital Essen, Hoffmann-La Roche Ltd | local squamous cell carcinoma of the head and neck, local squamous cell carcinoma of the head and neck, Diseases [C] - Cancer [C04] | | | | |
2020-001748-24: A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment.The Immunomodulation-CoV Assessment (ImmCoVA) study. |
|
|
| Not yet recruiting | 2 | 120 | Europe | Kineret, RoActemra, Solution for injection in pre-filled syringe, Concentrate for solution for infusion, Kineret, RoActemra | Karolinska University Hospital, Karolinska University Hospital, ME Infection diseases | COVID-19 infection in patients with respiratory distress., COVID-19 infection in patients with respiratory distress., Diseases [C] - Virus Diseases [C02] | | | | |
| Recruiting | 2 | 276 | Europe | Tocilizumab, Hydroxychloroquine, Azithromycin | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Instituto de Salud Carlos III | COVID-19 | 06/21 | 07/21 | | |
NCT04363853: Tocilizumab Treatment in Patients With COVID-19 |
|
|
| Active, not recruiting | 2 | 200 | RoW | Tocilizumab 20 MG/ML | Instituto Nacional de Cancerologia de Mexico, Roche Pharma AG | Sars-CoV2 | 12/24 | 12/24 | | |
2020-005331-78: A study of SAR444245 combined with other anticancer therapies for the treatment of participants with lung cancer or mesothelioma Un estudio de SAR4443245 en combinación con otras terapias anticancerígenas para el tratamiento de participantes con cáncer de pulmón o mesotelioma |
|
|
| Ongoing | 2 | 360 | Europe | Tocilizumab, cisplatino, NA, pembrolizumab, nab-paclitaxel, pemetrexed, carboplatino, nab paclitaxel, SAR444245, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Powder for dispersion for infusion, Keytruda, Pazenir, Abraxane | Sanofi-Aventis Recherche & Développement, SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT, Sanofi-Aventis Recherche & Développement | Pleural mesotheliomaNon-small cell lung cancer Mesotelioma Pleural Cáncer de Pulmón no microcítico, MesotheliomaLung cancer Mesotelioma Cáncer de pulmón, Diseases [C] - Cancer [C04] | | | | |
| Completed | 2 | 147 | Europe | Tocilizumab, (ACTEMRA®), Gemcitabine, nab-Paclitaxel, ABRAXANE® | Herlev Hospital, Celgene | Unresectable Pancreatic Carcinoma | 08/21 | 01/23 | | |
2021-000679-35: SATELITE “Salvage Therapy for Patients with Inadequate Response to Standard of Care Therapy in Granulomatosis with Polyangiitis” SATELITE "Traitement de sauvetage pour les patients ayant une réponse inadéquate au traitement de référence dans la granulomatose avec polyangéite" |
|
|
| Not yet recruiting | 2 | 42 | Europe | Concentrate for solution for infusion, Solution for injection, Tablet, Rituximab, ROACTEMRA, ORENCIA, Methotrexate, Mycophénolate mofétil, Azathioprine | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP), ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS | Granulomatosis with Polyangiitis Granulomatose avec polyangéite, Granulomatosis with Polyangiitis Granulomatose avec polyangéite, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2019-004438-40: Ipilimumab, nivolumab and tocilizumab in pretreated patients with advanced pancreatic cancer. Immunterapi og tocilizumab til patienter med fremskreden kræft i bugspytkirtlen. |
|
|
| Not yet recruiting | 2 | 30 | Europe | Concentrate for solution for infusion, Opdivo, Yervoy, RoActemra | Department of Oncology, Herlev & Gentofte Hospital, Department of Oncology, Herlev & Gentofte Hospital, Danish Cancer Society | Pretreated patients with advanced pancreatic cancer., Pretreated patients with advanced pancreatic cancer., Diseases [C] - Cancer [C04] | | | | |
2021-002028-19: Treatment of patients with acute myocardial infarction to avoid development of cardiogenic shock and lessen the injury of the cardiac muscle with Dobutamine and / or the IL-antagonist Tocilizumab Behandling af patienter med akut blodprop i hjertet for at undgå udvikling af kardiogent shock og mindske skaden på hjertemusklen med Dobutamin og / eller IL-hæmmeren Tociluzimab |
|
|
| Not yet recruiting | 2 | 100 | Europe | Concentrate for solution for infusion, RoActemra, Dobutrex® | Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Copenhagen University Hospital Rigshospitalet, Novo Nordisk Foundation, Simon Spies Fonden, Helge Peetz og Verner Peetz og hustru Vilma Peetz Legat | Acute Myocardial Infarction with increased risk of Cardiogenic Shock. Akut myokardieinfarkt med høj risiko for kardiogent shock., Acute myocardial infarction presenting within 24 hours from onset of symptoms and intermidate to high risk of developing cardiogenic shock. Akut blodprop i hjertet med debut af symptomer inden for 24 timer og intermediær til høj risiko for kardiogent shock., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
NCT03699631: PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant |
|
|
| Completed | 2 | 29 | US | Tacrolimus, Prograf, Methotrexate, Trexall, Tocilizumab, Actemra | Medical College of Wisconsin, National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI) | Hematologic Malignancy | 03/22 | 04/23 | | |
Nov IIT- Pyrex, NCT04652258: Pyrexia Management Using an IL-6 Antibody in BRAF+ Melanoma Patients Treated With Dabrafenib/ Trametinib +/- Immunotherapy |
|
|
| Recruiting | 2 | 20 | Europe | Actemra | University of Zurich | Pyrexia | 06/22 | 10/22 | | |
| Recruiting | 2 | 480 | Europe, Japan, US, RoW | Talquetamab, JNJ-64407564 | Janssen Research & Development, LLC | Hematological Malignancies | 03/26 | 12/26 | | |
|
|
|
|
|
2021-003747-22: Study of PHE885 in adult patients with relapsed and refractory Multiple Myeloma |
|
|
| Ongoing | 2 | 100 | Europe | PHE885, PHE885, Dispersion for infusion, ROACTEMRA - 20 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 10 ML 1 FLACONCINO, ROACTEMRA - 20 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 20 ML 1 FLACONCINO | Novartis Pharma AG, Novartis Farmacéutica, S.A., NOVARTIS PHARMA AG, Novartis Pharma AG | Adult participants with relapsed and refractory multiple myeloma after failure of 3 or more different prior lines of therapy, including failing an immunomodulatory drug (IMiD), a proteasome inhibitor (PI) and an anti-CD38 (cluster of differentiation 38) monoclonal antibody (mAb), and who have measurable disease at enrollment and documented evidence of progressive disease per IMWG criteria on the last prior therapy. Participants must be refractory to the last line of therapy., relapsed and refractory Multiple Myeloma, Diseases [C] - Cancer [C04] | | | | |
NCT05181397: The Efficacy and Safety of Tocilizumab for Severe RP-ILD Secondary to Systemic Diseases |
|
|
| Recruiting | 2 | 68 | RoW | Tocilizumab | Peking Union Medical College Hospital | Rapid Progressive Interstitial Lung Diseases | 09/22 | 09/22 | | |
| Terminated | 2 | 67 | Europe, US, RoW | Isatuximab, SAR650984, Sarclisa, Dexamethasone or equivalent, Fludarabine, Cytarabine, Liposomal daunorubicin, Daunorubicin (nonliposomal), Idarubicin, Filgrastim or equivalent, Mitoxantrone, Doxorubicin, Vincristine, Pegaspargase (PEG) Asparaginase, Cyclophosphamide, Etoposide, Methotrexate, L - Asparginase, Hydroxyurea, L - Asparaginase (Erwinase) | Sanofi | Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | 09/22 | 05/23 | | |
|
2022-001316-26: UVB: treatment of UVeitis in Behçet’s diseases with biologics |
|
|
| Not yet recruiting | 2 | 60 | Europe | Solution for injection in pre-filled pen, Solution for injection in pre-filled syringe, Humira 40mg, solution injectable en stylo prérempli, RoActemra 162 mg solution injectable en seringue préremplie | Assistance Publique Hôpitaux de Paris / DRCI, French Ministry of health | severe uveitis of Behçet’s disease, severe uveitis of Behçet’s disease, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT04395222: Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation |
|
|
| Active, not recruiting | 2 | 21 | US | Tocilizumab, Actemra, Fludarabine, Fludara, Melphalan, Alkeran, Anti-thymocyte globulin (rabbit), Thymoglobulin, Total Body Irradiation | Weill Medical College of Cornell University | Hematologic Malignancy, Bone Marrow Transplant | 09/22 | 05/27 | | |
2021-005744-29: EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA ENSAYO DE EFICACIA Y SEGURIDAD DEL EPCORITAMAB CON O SIN LENALIDOMIDA COMO TRATAMIENTO DE PRIMERA LÍNEA PARA SUJETOS CON LINFOMA DIFUSO DE CÉLULAS B GRANDES |
|
|
| Not yet recruiting | 2 | 180 | Europe, RoW | Epcoritamab, Lenalidomide, GEN3013, Concentrate for solution for injection, Capsule, hard, If the IMP has a marketing authorisation in the Member State concerned by this application, but the trade name and marketing authorisation holder are not fixed in the protocol, go to section D.2.2., RoActemra | Genmab A/S, GENMAB A/S, Genmab A/S, Genmab US, Inc. | B-cell Lymphoma Linfoma de linfocitos B, Lymphoma of B-cell origin Linfoma de origen de células B, Diseases [C] - Cancer [C04] | | | | |
2020-001767-86: trial comparing different doses of single-dose tocilizumab in adults with severe COVID-19 infection |
|
|
| Not yet recruiting | 2 | 90 | Europe | Tocilizumab, Concentrate for solution for infusion, RoActemra | University College Dublin, University College Dublin | COVID-19 infection, Coronavirus infection, Diseases [C] - Virus Diseases [C02] | | | | |
| Recruiting | 2 | 64 | Europe | Tocilizumab 20 Mg/mL Intravenous Solution, Actemra, MethylPREDNISolone Injectable Solution, Solumedrol | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Mauriziano Umberto I Hospital, Istituto Auxologico Italiano, Azienda Ospedaliera "Sant'Andrea", Azienda Ospedaliero, Universitaria Pisana | Graves Ophthalmopathy | 12/22 | 12/23 | | |
NCT04375228: Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs) |
|
|
| Recruiting | 2 | 30 | US | Rituximab, RITUXAN, Tocilizumab, ACTEMRA | Columbia University, Genentech, Inc. | Immune-related Adverse Events, Advanced Solid Tumor | 05/24 | 05/25 | | |
| Active, not recruiting | 2 | 41 | Europe | Tocilizumab 20 Mg/mL Intravenous Solution, RoActemra, L04AC07, Paclitaxel, L01CD01, Carboplatin, L01XA02, External beam radiotherapy | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Noordwest Ziekenhuisgroep | Esophageal Adenocarcinoma, Oesophageal Adenocarcinoma, Resectable Carcinoma | 10/22 | 04/28 | | |
NCT05957107: Phase II Trial of VDJ001 in Patients With Moderate-to-severe Active Rheumatoid Arthritis |
|
|
| Completed | 2 | 181 | RoW | Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection, Tocilizumab Injection, placebo control | Xiaoming Gong | Rheumatoid Arthritis | 06/23 | 06/23 | | |
NCT03999749: A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma |
|
|
| Active, not recruiting | 2 | 75 | US | Ipilimumab, Nivolumab, Tocilizumab | NYU Langone Health | Melanoma | 07/23 | 11/24 | | |
| Active, not recruiting | 2 | 18 | Europe | Rituximab, Infliximab, Tocilizumab | Cambridge University Hospitals NHS Foundation Trust | Giant Cell Arteritis, Takayasu Arteritis, Cogan Syndrome, Relapsing Polychondritis, Cryoglobulinemic Vasculitis, IgA Vasculitis, Polyarteritis Nodosa, Cutaneous Polyarteritis Nodosa, Primary Angiitis of Central Nervous System | 11/23 | 06/24 | | |
| Active, not recruiting | 2 | 402 | Europe | Tocilizumab Injection | National Cancer Institute, Naples | COVID-19 Pneumonia | 12/23 | 12/23 | | |
| Recruiting | 2 | 30 | Europe | Sodium Thiosulfate 25% Solution for Injection, NATRIUMTHIOSULFAT 25% | Hellenic Institute for the Study of Sepsis | COVID-19, Virus Diseases, Corona Virus Infection | 12/23 | 12/23 | | |
NCT03434730: Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation |
|
|
| Active, not recruiting | 2 | 46 | US | Total Body Irradiation, TBI, Cyclosporine, Sandimmune, Mycophenolate Mofetil, CellCept, Tocilizumab, Acemtra, Filgrastim, Granulocyte-Colony Stimulating Factor, Neupogen | Memorial Sloan Kettering Cancer Center | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases, Myeloproliferative Disorder, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Leukemia | 02/25 | 02/25 | | |
| Active, not recruiting | 2 | 75 | US | Tocilizumab, Tocilizumab 40mg, Tocilizumab 120mg, Standard of Care | University of Chicago | COVID-19 | 03/24 | 03/25 | | |
DOBERMANN, NCT05350592: Low-Dose Dobutamine and Single-Dose Tocilizumab in Acute Myocardial Infarction With High Risk of Cardiogenic Shock |
|
|
| Recruiting | 2 | 100 | Europe | Tocilizumab, RoActemra (Actemra), Dobutamine, Dobutrex, NaCl 0.9%, Saline isotonic | Rigshospitalet, Denmark, Novo Nordisk A/S, Simon Spies Fonden, Helge Peetz og Verner Peetz og hustru Vilma Peetz Legat | Acute Myocardial Infarction, Cardiogenic Shock | 03/25 | 06/25 | | |
tMG, NCT05067348: Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis |
|
|
| Recruiting | 2 | 64 | RoW | Tocilizumab Injectable Product | Tang-Du Hospital | Myasthenia Gravis, Generalized | 03/24 | 09/24 | | |
NCT04321993: Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients |
|
|
| Active, not recruiting | 2 | 363 | Canada | Baricitinib (janus kinase inhibitor), Remdesivir (antiviral) + barictinib (janus kinase inhibitor), Remdesivir (antiviral), Tocilizumab (interleukin 6 inhibitor) | Lisa Barrett, Nova Scotia Health Authority, Dalhousie University | COVID-19 | 04/24 | 04/24 | | |
RAIPONS, NCT04779957: Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy |
|
|
| Recruiting | 2 | 18 | Europe | Tocilizumab | University Hospital, Toulouse | Kidney Transplantation, Graft Failure | 10/24 | 10/24 | | |
| Recruiting | 2 | 34 | Europe | Mosunetuzumab, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) | GELLC (Grupo Español de Leucemia Linfocítica Crónica) | Richter Syndrome, Chronic Lymphocytic Leukemia | 06/28 | 10/29 | | |
| Recruiting | 2 | 36 | Europe | Tocilizumab 20 MG/ML [Actemra], RoActemra, Actemra, Sodium Chloride 0.9% Inj, Natriumchloride 0.9 % Inj | Soren Schou Olesen, Aarhus University Hospital, University of Aarhus, Viborg Regional Hospital, Stanford University, Haukeland University Hospital | Pancreatitis, Chronic | 06/26 | 06/26 | | |
| Recruiting | 2 | 100 | Europe | Tocilizumab before CAR-T cell infusion, Prophylactic, Tocilizumab at emerging CRS, On demand | Insel Gruppe AG, University Hospital Bern | Myeloma, Lymphoma, Leukemia | 12/26 | 06/27 | | |
| Not yet recruiting | 2 | 56 | Europe | Mosunetuzumab in combination with Zanubrutinib, LUNSUMIO in combination with BRUSINKA | Fondazione Italiana Linfomi - ETS | Follicular Lymphoma | 09/28 | 09/33 | | |
NCT03821246: Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy |
|
|
| Recruiting | 2 | 68 | US | Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Tocilizumab, Actemra, Etrumadenant, AB928 | David Oh, Genentech, Inc. | Prostate Adenocarcinoma, Prostate Cancer, Localized Prostate Cancer | 02/25 | 02/25 | | |
| Recruiting | 2 | 32 | Europe | Kineret, Humira, Stelara, Cosentyx, Roactemra, Rituximab | Assistance Publique - Hôpitaux de Paris | Inflammatory Disease, Autoimmune Diseases | 11/25 | 11/25 | | |
NCT05233397: ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma |
|
|
| Recruiting | 2 | 38 | Europe, Canada, US, RoW | Tocilizumab, ACTEMRA® | Nationwide Children's Hospital, Children's Hospital Colorado | Adamantinomatous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma | 12/25 | 12/27 | | |
NCT03787290: Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder |
|
|
| Suspended | 2 | 35 | US | Tocilizumab, Placebo, Saline, Whole-Body Hyperthermia, Heckel HT3000 | Massachusetts General Hospital, heckel medizintechnik GmbH | Major Depressive Disorder | 12/27 | 03/28 | | |
NCT04688021: A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT. |
|
|
| Recruiting | 2 | 46 | RoW | Cytarabine, Busulfan, Cyclophosphamide, Me-CCNU, Rabbit antithymocyte globulin, Tocilizumab, Allogeneic HSCT, Cyclosporin A, Mycophenolate Mofetil, MTX | Yi Luo | Leukemia, Graft-versus-host-disease | 12/24 | 12/24 | | |
OPTec, NCT05972135: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma |
|
|
| Recruiting | 2 | 75 | US | Teclistamab, (TECVAYLI™), Talquetamab, TALVEY™, Tocilizumab, Actemra | SCRI Development Innovations, LLC, Janssen Research & Development, LLC | Multiple Myeloma | 01/25 | 02/25 | | |
| Recruiting | 2 | 200 | US | Tocilizumab | University of Chicago | Sickle Cell Disease, Acute Chest Syndrome | 04/25 | 01/26 | | |
| Active, not recruiting | 2 | 385 | US | tocilizumab, Actemra®, Placebo, Placebo for tocilizumab, Placebo for Actemra®, Standard of Care Triple IS, calcineurin inhibitor: (tacrolimus (Prograf ®)), anti-proliferative treatment: (mycophenolate mofetil ),, MMF, CellCept®, Myfortic®, enteric-coated mycophenolate sodium, steroids: methylprednisolone/prednisone | National Institute of Allergy and Infectious Diseases (NIAID), PPD | Heart Transplant | 04/25 | 04/25 | | |
ChiCTR2400084715: A Study on the Efficacy and Safety of Telitacicept Treatment versus Tacrolimus Treatment in Newly Diagnosed AchR-Positive Generalized Myasthenia Gravis |
|
|
| Not yet recruiting | 2 | 124 | | Subjects in the Tocilizumab group received a subcutaneous injection of 240mg weekly.; Subjects in the Tacrolimus group received oral treatment with a daily dose of 3mg of Tacrolimus. | Peking University People's Hospital; Peking University People's Hospital, The research was funded by the National Natural Science Foundation of China (81303013) | myasthenia gravis | | | | |
NRG-BN010, NCT04729959: Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma |
|
|
| Recruiting | 2 | 53 | US | Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Conventional Surgery, Fractionated Stereotactic Radiation Therapy, Fractionated Stereotactic Radiotherapy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Tocilizumab, Actemra, IL-6 receptor monoclonal antibodies: tocilizumab, Immunoglobulin G1, Anti-(Human Interleukin 6 Receptor) (Human-Mouse Monoclonal MRA Heavy Chain), Disulfide with Human-Mouse Monoclonal MRA Kappa-Chain, Dimer, MRA, R-1569, RoActemra | National Cancer Institute (NCI), NRG Oncology | Diffuse Astrocytoma, IDH-Wildtype, Recurrent Glioblastoma | 06/25 | 06/25 | | |
GO43075, NCT04980222 / 2021-001647-28: A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma |
|
|
| Active, not recruiting | 2 | 46 | Europe, US | Glofitamab, Tocilizumab, Doxorubicin, Vincristine, Prednisone, Rituximab, Cyclophosphamide | Hoffmann-La Roche | Lymphoma | 06/25 | 06/25 | | |
NCT05846789: Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers |
|
|
| Recruiting | 2 | 168 | US | Carboplatin, Tocilizumab | Kathy Miller, Genentech, Inc. | Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-low Breast Cancer | 12/26 | 12/26 | | |
MTXinGCA, NCT05623592: Methotrexate as Remission Maintenance Therapy After Remission-Induction With Tocilizumab and Glucocorticoids in Giant Cell Arteritis |
|
|
| Active, not recruiting | 2 | 52 | Europe | Methotrexate, Sodium chloride | University of Bonn | Giant Cell Arteritis | 11/25 | 11/25 | | |
| Withdrawn | 2 | 10 | RoW | Tocilizumab | Sun Yat-sen University | Tocilizumab, Thyroid Associated Ophthalmopathy | 09/23 | 09/23 | | |
NCT05845723: Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome |
|
|
| Recruiting | 2 | 81 | RoW | tocilizumab, ACTEMRA®, tofacitinib, Xeljanz®, cyclophosphamide, Endoxana | Peking Union Medical College Hospital | Aneurysm, Behcet Syndrome, Vascular Type | 06/26 | 06/27 | | |
| Not yet recruiting | 2 | 42 | Europe | Rituximab, Mabthera, Tocilizumab, RoActemra, Abatacept, Orencia | Assistance Publique - Hôpitaux de Paris, URC-CIC Paris Descartes Necker Cochin | Granulomatosis With Polyangiitis, Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | 09/26 | 01/27 | | |
NCT03708224: Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck |
|
|
| Recruiting | 2 | 55 | US | Atezolizumab, Tecentriq, Tocilizumab, Actemra, Tiragolumab, anti-TIGIT | Alain Algazi, Genentech, Inc. | Cancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck Cancer | 06/27 | 06/27 | | |
NCT06043674: A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation |
|
|
| Recruiting | 2 | 66 | US | Glofitamab, RO7082859, Obinutuzumab, RO5072759, GA101, GAZYVA, GAZYVARO, Polatuzumab Vedotin, Atezolizumab, Tecentriq, Tocilizumab, Actemra | Christine Ryan, Genentech, Inc. | Chronic Lymphocytic Leukemia, Richter's Transformation | 01/28 | 01/33 | | |
MorningSun, NCT05207670: A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies |
|
|
| Active, not recruiting | 2 | 345 | US | Mosunetuzumab (Cohorts A-C), Mosunetuzumab (Cohorts D-E), Tocilizumab | Genentech, Inc. | Non-Hodgkin Lymphoma | 07/28 | 07/28 | | |
| Recruiting | 2 | 350 | Canada, US | Tocilizumab, ACTEMRA, Placebo for Tocilizumab | National Institute of Allergy and Infectious Diseases (NIAID) | Lung Transplant | 01/29 | 01/29 | | |
GOlDiLOX, NCT05833763: A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure. |
|
|
| Recruiting | 2 | 42 | RoW | Glofitamab, Pirtobrutinib, Obinutuzumab, Tocilizumab | Australasian Leukaemia and Lymphoma Group | Mantle Cell Lymphoma, Mantle Cell Lymphoma Refractory | 04/32 | 04/37 | | |
| Recruiting | 1/2 | 48 | | | Royal Brisbane and Women's Hospital, National Health & Medical Research Council | Acute graft versus host disease (GVHD) post HLA-matched allogeneic haematopoietic progenitor cell transplantation (HPCT) | | | | |
| Withdrawn | 1/2 | 150 | | | QIMR Berghofer Medical Research Institute, QIMR Berghofer Medical Research Institute | COVID-19 | | | | |
| Completed | 1/2 | 307 | Europe, Canada, US, RoW | Axicabtagene Ciloleucel, Yescarta®, Fludarabine, Cyclophosphamide, Levetiracetam, Tocilizumab, Dexamethasone, High-dose methylprednisolone, Bendamustine, Rituximab, Doxorubicin, Prednisone, Vincristine, Ifosfamide, Carboplatin, Etoposide, Gemcitabine, Oxaliplatin, Cisplatin, Methylprednisolone | Kite, A Gilead Company | Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL) | 07/23 | 07/23 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NCT03467256: CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL |
|
|
| Active, not recruiting | 1/2 | 18 | RoW | Chimeric Antigen Receptor T-Cell Therapy, Fludarabine, Cyclophosphamide, Tocilizumab, Cytarabine, Etoposide, Dexamethasone | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | B-cell Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Pediatric | 10/20 | 10/25 | | |
NCT04499573: Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL |
|
|
| Active, not recruiting | 1/2 | 50 | RoW | CD19/CD22 CAR-T, Fludarabine, Cyclophosphamide, Cytarabine, Etoposide, Dexamethasone, Tocilizumab, Allogeneic HSCT | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | B-ALL | 03/22 | 03/27 | | |
NCT04082910: Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells |
|
|
| Recruiting | 1/2 | 30 | RoW | Metoprolol, metoprolol, infliximab, etanercept, tocilizumab and/or other agents | Chinese PLA General Hospital | Solid Tumor, Hematological Malignancy | 12/22 | 12/23 | | |
2022-001040-23: Treatment of relapsed or refractory B-cell lymphoma with CAR-T therapy produced by a new technology. Tratamiento del linfoma de células B en recaída o refractario con terapia CAR-T producida por una nueva tecnología. |
|
|
| Not yet recruiting | 1/2 | 27 | Europe | TranspoCART19, Cyclophosphamide, Fludarabina, Bendamustina, Tocilizumab, Cetuximab, Injection/infusion, Powder for solution for injection/infusion, Concentrate for solution for injection/infusion, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, , Genoxal 25mg/ml, Fludarabina Teva 25 mg/ml, Bendamustina Tillomed 2,5 mg/ml, RoActemra 20 mg/m, Erbitux 5 mg/ml | Instituto de Investigación Biomédica de Salamanca (IBSAL) - IECSCYL, Instituto de Salud Carlos III | Relapsed or refractory B-cell lymphoma Linfoma de células B en recaída o refractario, Relapsed or refractory B-cell lymphoma Linfoma de células B en recaída o refractario, Diseases [C] - Cancer [C04] | | | | |
GO40554, NCT03677154 / 2018-001127-40: Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma |
|
|
| Active, not recruiting | 1/2 | 188 | Europe, US, RoW | Mosunetuzumab Intravenous (IV), Mosunetuzumab Subcutaneous (SC), Polatuzumab Vedotin, Tocilizumab | Hoffmann-La Roche | Diffuse Large B-cell Lymphoma | 08/25 | 08/25 | | |
|
|
NCT04066114: Treg Modulation With CD28 and IL-6 Receptor Antagonists |
|
|
| Completed | 1/2 | 10 | US | lulizumab pegol, BMS-931699, antithymocyte globulin (rabbit), ATG (rabbit), Thymoglobulin®, methylprednisolone, Solu-Medrol ®, tocilizumab, Actemra®, Prednisone, prednisone tablets, Rayos®, everolimus, Zortress®, belatacept, Nulojix®, mycophenolate mofetil, MMF, CellCept®, mycophenolic acid, Myfortic® | National Institute of Allergy and Infectious Diseases (NIAID), Bristol-Myers Squibb, Clinical Trials in Organ Transplantation | Living-Donor Kidney Transplant, Kidney Transplant Recipients | 09/23 | 09/23 | | |
GO40515, NCT03677141 / 2018-001039-29: A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma |
|
|
| Completed | 1/2 | 117 | Europe, US, RoW | Mosunetuzumab, Polatuzumab Vedotin, Rituxumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tocilizumab | Hoffmann-La Roche | B-cell Non-Hodgkin Lymphoma | 10/23 | 10/23 | | |
|
2021-001060-23: A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination with Tiragolumab with or Without Atezolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma |
|
|
| Not yet recruiting | 1/2 | 118 | Europe | Mosunetuzumab, Tocilizumab, Atezolizumab, Tiragolumab, RO7030816, RO4877533, RO5541267, RO7092284, Solution for injection, Concentrate for solution for infusion, RoActemra®, Tecentriq® | F. Hoffman-La Roche Ltd, F.Hoffman-La Roche Ltd | Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL), Non-Hodgkin Lymphoma is a cancer of the lymphatic system. It develops when the body makes abnormal B lymphocytes., Diseases [C] - Cancer [C04] | | | | |
NCT05315713: An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma |
|
|
| Completed | 1/2 | 8 | Europe, Canada, US, RoW | Mosunetuzumab SC, Tiragolumab, Atezolizumab, Tocilizumab | Hoffmann-La Roche | Non-Hodgkin Lymphoma, Follicular Lymphoma | 07/23 | 07/23 | | |
NCT03867617: Cell Therapy for Immunomodulation in Kidney Transplantation |
|
|
| Active, not recruiting | 1/2 | 12 | Europe | Regulatory T cells, Tocilizumab, Bone marrow, Kidney transplant, Immunosuppressive drug therapy | Thomas Wekerle, University Hospital Regensburg | Kidney Transplantation | 06/24 | 06/29 | | |
| Not yet recruiting | 1/2 | 12 | NA | ToleraCell-001, ToleraCell-002, DFI-105, Etanercept, Tocilizumab, Sirolimus | Diabetes Free, Inc. | Diabetes Mellitus Type 2 - Insulin-Treated | 01/26 | 06/26 | | |
| Active, not recruiting | 1/2 | 422 | Europe, Canada, US | Mosunetuzumab (IV), BTCT4465A, Mosunetuzumab (SC), Polatuzumab vedotin, Tocilizumab, Rituximab | Hoffmann-La Roche | B-cell Non-Hodgkin Lymphoma | 01/24 | 07/25 | | |
|
|
|
NP39488, NCT03533283: An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma |
|
|
| Active, not recruiting | 1/2 | 280 | Europe, US, RoW | Glofitamab, RO7082859, Atezolizumab, Obinutuzumab, Tocilizumab, Actemra, Polatuzumab Vedotin, 89Zr-Df-IAB22M2C | Hoffmann-La Roche | Non-Hodgkins Lymphoma | 09/26 | 09/26 | | |
| Active, not recruiting | 1/2 | 645 | Europe, US, RoW | Atezolizumab, Enfortumab Vedotin, Niraparib, Magrolimab (Hu5F9-G4), Tiragolumab, Sacituzumab Govitecan, Tocilizumab, Cisplatin, Gemcitabine | Hoffmann-La Roche, Gilead Sciences, Inc., GlaxoSmithKline plc, Seattle Genetics and Astellas | Urothelial Carcinoma, Bladder Cancer | 10/24 | 05/26 | | |
|
BP41072, NCT04077723: A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 1/2 | 498 | Europe, US, RoW | Englumafusp alfa, A CD19 Targeted 4-1BB Ligand; RO7227166, Obinutuzumab, Gpt, RO5072759, Gazyva, Gazyvaro, Glofitamab, CD20-TCB, RO7082859, Tocilizumab, Actemra, RoActemra | Hoffmann-La Roche | Lymphoma, Non-Hodgkin | 03/27 | 03/27 | | |
NP30179, NCT03075696: A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 1/2 | 860 | Europe, Canada, US, RoW | Glofitamab, RO7082859, Obinutuzumab, RO5072759, GA101, Gazyva®, Gazyvaro™, Tocilizumab, Actemra®, Roactemra® | Hoffmann-La Roche | Non-Hodgkin's Lymphoma | 08/25 | 08/25 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Active, not recruiting | 1/2 | 675 | Europe, US, RoW | Atezolizumab, Cobimetinib, RO6958688, Docetaxel, CPI-444, Pemetrexed, Carboplatin, Gemcitabine, Linagliptin, Tocilizumab, Ipatasertib, Bevacizumab, Sacituzumab Govitecan, Radiation, Evolocumab, Tiragolumab, XL092, Zanzalintinib, Camonsertib | Hoffmann-La Roche | Carcinoma, Non-Small-Cell Lung | 09/25 | 11/26 | | |
|
